Company |
University/Non-Profit [Scientist] |
Type of Agreement |
Product Area |
Details (Month) |
Affymetrix Inc. |
National Cancer Institute |
Technology access |
Affymetrix GeneChip technology |
Agreement allows biomedical research community broad access to Affymetrix's GeneChip probe array technology; volume price discounts are available, with specific terms to be negotiated directly with Affymetrix by each institution; terms designed to not interfere with traditions of publishing and collaboration (4/20) |
University of California |
Technology access |
Affymetrix GeneChip technology |
University of California signed Academic Access deal, which gives preferential access to Affymetrix's standard and custom GeneChip arrays, instrumentation and software to monitor gene expression; terms and conditions specially designed to not interfere with publishing (6/14) |
|
Agritope Inc. |
University Technologies International Inc. (private technology commercialization company owned by the University of Calgary [Thomas Back] |
Research collaboration |
Technology for synthesizing brassinosteroids with high biological activity |
Back will synthesize compounds in his laboratory and deliver them to Agritope for evaluation and commercial development; Agritope has an option to obtain an exclusive royalty-bearing license to commercialize the technology (6/3) |
Salk Institute for Biological Studies and the Institute of Cell and Molecular Biology of the University of Edinburgh |
Research collaboration |
Functional genomics that uses Agritope's ACTTAG Gene Discovery program to generate genetically modified seed that will be screened for a variety of traits, such as disease resistance, insect resistance, new morphologies, abiotic stress tolerance, improved flowering characteristics, herbicide tolerance and improved nutritional qualities |
Five-year research program; basic program will be carried out at Agritope; discoveries at both institutes arising from the ACTTAG research will be licensed to Agritope, which plans to seek commercial collaborators (1/25) |
|
Angiotech Pharmaceut- |
University of Pennsylvania |
License |
Use of paclitaxel in the treatment of Alzheimer's disease |
Angiotech acquired an exclusive license to intellectual property that includes U.S. patent No. 5,580,898 (1/25) |
Bio-Technology General Corp. |
Yeda Research and Development Co. Ltd. (licensing arm of The Weizmann Institute of Science in Rehovat, Israel) [Leah Eisenbach] |
Research and license agreement |
Peptide-based vaccines for the treatment of cancer; initial efforts to focus on transitional cell carcinoma of the bladder, breast and colon |
Bio-Technology General will provide research funding and make milestone payments, as well as pay royalties on any peptide-based vaccines resulting from the research which the company markets under the exclusive license (4/27) |
Massachusetts General Hospital/Children's Hospital of Boston [Lawrence Weissbach, Valerae Lewis and Michael O'Reilly] |
Research and license agreement |
Use of recombinant plasminogen-related peptide as an angiogenesis inhibitor for the treatment of cancer |
Bio-Technology General will produce rPRP and conduct research at its facility in Rehovat, Israel, in collaboration with Weissbach; the company will fund the research and make milestone payments, as well as pay royalties on resulting therapeutic products that Bio-Technology markets under the exclusive license (4/27) |
|
Calypte Biomedical |
Chinese National Center for AIDS Prevention and Control, and Chinese Academy of Preventive Medicine |
Distribution agreement |
Non-invasive urine HIV test |
Calypte's test selected for wide-scale use within the Chinese health care system, including the Chinese Academy of Preventive Medicine, which will use the product exclusively (3/11) |
Digene Corp. |
Mexican National Institute of Public Health, the Mexican Institute for Social Security and the Johns Hopkins School of Public Health |
Clinical trial collaboration |
Evaluation of Digene's human papillomavirus test as a primary cervical cancer screening to determine if screening will result in improved and more cost-effective cervical cancer prevention; trial will enroll 7,500 women |
Financial details ND (1/26) |
Endocyte Inc.* |
National Cancer Institute (NCI) |
Collaborative Research and Development Agreement (CRADA) |
Use of the vitamin folate to deliver chemotherapeutic drugs to cancer cells |
Endocyte will select compounds from NCI's repository of anticancer drugs to link to folate; NCI and Endocyte will jointly test the resulting compounds (5/12) |
EntreMed Inc. |
National Cancer Institute (NCI) |
Collaborative Research and Development Agreement (CRADA) |
Use of 20methoxyes-tradiol (2ME2) as an anticancer agent (angiogenesis inhibitor) |
EntreMed scientists will provide 2ME2 to the NCI for collaborative studies in preclinical pharmacology, toxicology, and anticipated clinical trials; together with NCI, the company will design, review and interpret the results of preclinical studies required for investigational new drug application (4/6) |
GenoPlex Inc.* |
Massachusetts General Hospital [Rudolph Tanzi] |
License |
Discoveries related to a2-macroglobulin (a2M) genes variants linked to Alzheimer's disease |
GenoPlex exclusively licensed several patent applications related to the diagnosis and treatment of diseases associated with a2M, and is using the technology in its Alzheimer's program (3/2) |
Gen-Probe Inc.* and Chiron Corp. |
America's Blood Centers |
Technology evaluation agreement |
Use of Transcription- Mediated Amplification, a technology for nucleic acid testing developed by Gen-Probe and marketedby Chiron; allows for simultaneous testing of HIV-1 and hepatitis C virus RNAs |
Chiron, Gen-Probe and ABC are co-sponsors of studies designed to evaluate TMA technology; Chiron and Gen-Probe will supply instrumentation and reagent kits to ABC, which will conduct this testing at multiple centers nationwide (3/22) |
American Red Cross |
Technology evaluation agreement |
Use of Transcription Mediated Amplification, a technology for nucleic acid testing developed by Gen-Probe and marketed by Chiron; allows for simultaneous testing of HIV-1 and hepatitis C virus RNAs |
Gen-Probe and Chiron will provide instruments and nucleic acid testing kits to the Red Cross, which will conduct the testing at the organization's National Genome Testing Laboratory in San Diego (1/4) |
|
Genset |
Johns Hopkins University School of Medicine [Ann Pulver] |
Research collaboration |
Identification and cloning of schizophrenia susceptibility genes; collaboration uses of Genset's single nucleotide polymorphism technology (densely spaced sets of proprietary biallelic markers) and linkage disequilibrium association strategies for analysis of a Johns Hopkins bank of 1,800 DNA samples collected from more than 300 families containing one or more members diagnosed with schizophrenia |
Two-year research agreement granting Genset access to bank DNA samples from families with one or more schizophrenic members (5/5) |
Genzyme Corp. |
The Toronto Hospital [Richard Weisel] |
Research and development collaboration |
Use of cell-based therapy to treat cardiovascular disease; research will focus initially on developing a treatment that uses cultured autologous cardiomyocyte, to replace damaged heart tissue |
Genzyme acquires rights to all intellectual property and technology relating to existing cardiomyocyte and cell therapy research performed by Weisel and associates, and will solely own or have access to all new technology produced by the collaboration; Genzyme paid an undisclosed upfront fee to acquire the rights noted above and for an option to license additional technologies developed outside the collaboration; Genzyme will also make milestone and royalty payments on covered products (1/21) |
Genzyme Molecular Oncology Hyseq Inc. |
Children's Hospital Medical Center in Boston [Judah Folkman and Michael O'Reilly] |
License |
Anti-angiogenic protein for use in treating cancer |
In exchange for an exclusive word-wide license, GMO will pay an upfront fee, make milestone payments and pay royalties on sales |
Imperial Cancer Research Technology Ltd. (wholly owned subsidiary of Imperial Cancer Research Fund in the U.K.) |
License |
Use of naturally soluble forms of human ectoapyrases as anti-clotting agents |
Hyseq acquired certain exclusive rights; further details ND (2/2) |
|
IDEC Pharmaceuticals |
National Cancer Institute [Ira Pastan] |
Cooperative Research and Development Agreement |
Development and therapeutic use of prostate-specific PAGE antigens in therapeutic vaccines for prostate cancer; vaccines will employ IDEC's Provax adjuvant to induce cytotoxix T lymphocyte responses to tumor-associated antigens |
IDEC will collaborate on further studies of PAGE antigens with Pastan's laboratory, in which the family of antigens was discovered; further details ND (2/16) |
University of California [Chris Hughes] |
Research collaboration |
Identification of genes specifically expressed by tumor endothelium in orderto find anti-angiogenic targets for treating cancer |
IDEC will collaborate with Hughes' laboratory; details ND (2/16) |
|
IGEN International Inc. |
John Wayne Cancer Institute [Dave Hoon] |
Expanded research collaboration |
Use of IGEN's Origen technology to develop diagnostics, especially for cancer; Hoon has already developed a blood test for early detection of micrometastases |
IGEN expanded the collaboration to focus on additonal cancer diagnostics for early detection and monitoring of progression; IGEN obtained an option to exclusively license any tests developed by Hoon (1/12) |
Immune Response Corp. |
University of Maryland Biotechnology Institute (Institute of Human Virology) [Robert Gallo] |
License |
Use of 2 technologies to potentially treat a varietyof diseases; one centers on hCG associated factor (HAF), a naturally occurring peptide that may have applications in cancer (by promoting bone marrow growth differentiation) and in HIV prevention and treatment; the 2nd centers on chemokine technology |
Immune Response will issue restricted stock to UMBI as an initial license fee, will sponsor a 5-year renewable research program at IHV, and will initiate a research effort of its own at the UMBI facility; Immune Response will have a right of first refusal to license all new technology related to HAF and chemokines that is subsequently developed by IHV; Immune Response agreed to use all reasonable efforts to commercialize products and will incur patenting costs (5/10) |
Immunomedics Inc. |
National Cancer Institute [Susanna Rybak] |
Cooperative Research and Development Agreement |
Development and use of antibody-conjugated recombinant cytotoxic ribonucleases as a potential new class of anticancer agents; could potentially be directed against both blood cancers and solid tumors |
NCI will contribute special recombinant toxins that destroy the cancer cells' RNA; Immunomedics will contribute antibodies, drugs and certain peptides, which target various cancers; the company will collaborate on studies with NCI's research team and will retain commercial rights (2/22) |
Inhibitex Inc. |
BioResearch Ireland (national agency commercializing biotechnology research from Irish universities) [Timothy Foster] |
Research and license agreement |
Discovery and characterization of cell surface adhesions from Staphylococcus aureus and coagulase-negative staphylococci |
Inhibitex will use novel adhesions discovered in the collaboration to develop its pipeline of immunotherapeutics targeting the prevention and treatment of hospital-acquired, antibiotic-resistant staphylococcal infections; research will be conducted at BI's National Pharmaceutical Biotechnology Centre and at the Moyne Institute of Preventive Medicine (both at Trinity College in Dublin) (4/13) |
Inhibitex Inc. |
University of Pavia in Italy |
Research and license agreement |
Use of the university's existing library of proprietary monoclonal antibodies to develop products to treat various antibiotic-resistant infections |
Inhibitex gains worldwide rights to the library, as well as to future discoveries resulting from the collaboration, in the field of treatments for resistant infections (1/6) |
Inhibitex Inc. |
University of Minnesota [Margaret Hostetter] |
License |
Use of MSCRAMM (microbial surface components recognizing adhesive matrix) surface proteins from Candida albicans for developing vaccines to prevent fungal infections caused by the organism |
Inhibitex exclusively licensed rights to the protein; further details ND (6/2) |
Lexicon Genetics* |
Johns Hopkins University |
Research collaboration |
Lexicon will create custom knockout mice for gene of interest using homologous recombination technologies |
Financial terms ND, though company said academic collaborations allow for "significant potential downstream benefits" (6/10) |
Lexicon Genetics* |
Pennsylvania State University |
Research collaboration |
Lexicon will create custom knockout mice for gene of interest using homologous recombination technologies |
Financial terms ND, though company said academic collaborations allow for "significant potential downstream benefits" (6/10) |
University of Southern California |
Research collaboration |
Lexicon will create custom knockout mice for gene of interest using homologous recombination technologies |
Financial terms ND, though company said academic collaborations allow for "significant potential downstream benefits" (6/10) |
|
University of Rochester |
Research collaboration |
Lexicon will create custom knockout mice for gene of interest using homologous recombination technologies |
Financial terms ND, though company said academic collaborations allow for "significant potential downstream benefits" (6/10) |
|
Indiana University School of Medicine |
Research collaboration |
Lexicon will create custom knockout mice for gene of interest using homologous recombination technologies |
Financial terms ND, though company said academic collaborations allow for "significant potential downstream benefits" (6/10) |
|
The Max Planck Society |
Research collaboration |
Lexicon will create custom knockout mice for gene of interest using homologous recombination technologies |
Financial terms ND, though company said academic collaborations allow for "significant potential downstream benefits" (6/10) |
|
InSite Vision Inc. |
University of California |
Option agreement |
Use of TIGR gene technology for the treatment and prevention of glaucoma |
InSite signed option agreement for therapeutic rights to issued and pending gene patents and applications; TIGR had previously licensed diagnostic and prognostic rights; financial terms ND (4/26) |
Maxygen Inc. |
California Institute of Technology [Frances Arnold] |
License and research collaboration |
Use of Staggered Extension Process directed evolution technology developed in Arnold's lab; technology has applications in Maxygen's "DNA Shuffling" programs for nucleic acid recombination |
Maxygen obtained exclusive worldwide license and research collaboration; further details ND (4/27) |
Millennium Pharmaceuticals Inc. |
Partners HealthCare System Inc. (affiliate of Harvard University Medical School) |
Research collaboration |
Creation of a series of long-term research collaborations in gene discovery and target identification; Millennium also gains ability to clinically validate drugs and diagnostics |
A comprehensive research plan will be established annually; Millennium will use its drug discovery platform to advance mutual scientific interests, and will make available to partners various technologies; Partners will provide assays, tissue samples, animal models and clinical and research expertise; financial details ND (3/23) |
MitoKor |
Indian Institute of Science in Bangalore |
Sponsored research |
Synthesis of novel intermediates for drug discovery |
MitoKor will support a team of organic chemists at IIS, who will synthesize novel intermediates for MitoKor; the collaboration will expire in one year, but may be extended by mutual agreement; MitoKor has rights to compounds developed in the program and IIS retains rights to certain synthetic processes (2/16) |
Nanogen Inc. |
Mayo Clinic |
Beta testing site agreement |
Testing of Nanogen's molecular identification system for analyzing single nucleotide polymorphisms and repetitive DNA sequences |
Terms ND (3/31) |
Bode Technology Group |
Beta testing site agreement |
Testing of Nanogen's molecular identification system for analyzing single nucleotide polymorphisms and repetitive DNA sequences |
Terms ND (3/31) |
|
University of Texas Southwestern Medical Center at Dallas |
Beta testing site agreement |
Testing of Nanogen's molecular identification system for analyzing single nucleotide polymorphisms and repetitive DNA sequences |
Terms ND (3/31) |
|
Ontogeny Inc.* |
University of California San Francisco [Ervin Epstein] |
Research collaboration |
Ontogeny will evaluate therapetic potential of compounds to treat basal cell carcinoma using a model of the disease developed at UCSF |
Terms ND (3/2) |
Brigham and Women's Hospital and the Center for Cutaneous Oncology at the Dana-Farber Cancer Institute |
Research collaboration |
Elucidation of molecular pathways involved in basal cell carcinoma and identification of potential therapeutics |
The Division of Dermatology at BWH and the Center for Cutaneous Oncology at DFCI will provide expertise in cell culture and transgenic animals, and human basal cell carcinoma cells; Ontogeny will use the cells to define further the role of the patched protein in the development of the disease, and will use the cells and tissue samples to evaluate leads (3/2) |
|
OraPharma Inc.* |
Children's Medical Center Corp. |
Separate license and sponsored research agreements |
License is for manufacture and sale of Children's Medical products for bone and soft tissue regeneration for the dentistry and orthopedics markets: OsteoIntegrin, Osteo Morphin and RIS (Rapid Implant Stabilizer); under sponsored research agreement, Children's Medical will perform R&D activities based on bone and tissue regeneration and wound healing technologies |
OraPharma gains exclusive world-wide license to manufacture and sell 3 products; OraPharma has exclusive worldwide license to manufacture and sale of products developed under research agreement (2/3) |
Pharmacopeia Inc. |
Harvard University (Institute of Chemistry and Cell Biology) |
Research collaboration |
Use of Pharmacopeia's platform for small-molecule combinatorial chemistry ECLiPS |
Pharmacopeia scientists will conduct research at ICCB, in addition to sharing technology; further details ND (3/17) |
ProScript Inc. |
National Cancer Institute (NCI) |
Cooperative Research and Development Agreement |
Development of ProScript's anticancer agent and proteasome inhibitor, PS-341, which targets protein degradation machinery |
NCI will sponsor several Phase I clinical trials through the Cancer Therapy Evaluation Program (1/7) |
Protein Sciences Corp.* |
Texas A&M University [Max Summers and Gale Smith] |
Agreement to combine intellectual property and knowhow; Protein Sciences may sub-license technologies to third parties |
Use of baculovirus expression vector system for protein production |
Deal combines Texas A&M's patents with Protein Sciences' commercial-scale expression technology, with the goal of sublicensing combined platform to third parties; Texas A&M will continue to work directly with licensees whose products would not benefit from the added value of Protein Sciences' production technologies (2/8) |
SYNSORB Biotech Inc. (Canada) |
Consortium that includes the Canadian Bacterial Disease Network, the Canadian Microbiology Consorium Inc., the University of Alberta, the University of British Columbia, and Novadex Pharmaceuticals Ltd. |
License agreement |
Use of compounds for the treatment of lung complications associated with cystic fibrosis; carbohydrate-based compounds appear to reduce viscosity of mucous and inhibit proliferation of bacteria in the lungs of CF patients |
Details ND (6/10) |
Variagenics Inc. |
McGill University [Rima Rozen] |
License agreement |
Use of methylenetetra- hydrofolate reductase (MTHFR) gene for diagnostic and therapeutic purposes; variations are associated with cardiovascular disease; tests would have utility in early diagnosis and selection of patients for whom treatment with folate would reduce risk |
Variagenics licensed exclusive rights; further details ND (4/1) |
** Unless otherwise noted, the stock symbols for publicly traded biotechnology companies are listed on pp. 12 and 13. | ||||
